SEC 13F Intelligence

Managers / Q4 2022 · view latest →

Cheyne Capital Management (UK) LLP

CIK 0001390457 · STORNOWAY HOUSE, 13 CLEVELAND ROW, LONDON, X0, SW1A 1DH · 011-44(0)2070317450

Reported Value
$57M
Q4 2022
Positions
59
Filings on Record
22
2019–present window
Filed
Feb 10, 2023
original filing

Summary

Cheyne Capital Management (UK) LLP reported $57M in U.S.-listed holdings across 59 positions for Q4 2022.

Its largest position, Activision Blizzard, represents 13.8% of the portfolio.

Compared with Q3 2022, the fund opened 38 new positions and exited 14.

Portfolio Metrics

Turnover
+29.4%
vs prior filed quarter
Top-10 Concentration
+46.4%
share of reported value
Largest Position
+13.8%
Activision Blizzard
New / Exited
38 / 14
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $107MQ2 ’19: $138MQ3 ’19: $158MQ3 ’19Q4 ’19: $165MQ1 ’20: $97MQ2 ’20: $148MQ2 ’20Q3 ’20: $203MQ4 ’20: $198MQ1 ’21: $158MQ1 ’21Q2 ’21: $220MQ3 ’21: $168MQ4 ’21: $154MQ4 ’21Q1 ’22: $159MQ2 ’22: $118MQ3 ’22: $47MQ3 ’22Q4 ’22: $57MQ1 ’23: $32MQ2 ’23: $27MQ2 ’23Q3 ’23: $35MQ4 ’23: $28Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 84.6%Other: 9.1%ADR: 3.8%ETP: 2.5%
  • Common Stock · 84.6% · $48M
  • Other · 9.1% · $5M
  • ADR · 3.8% · $2M
  • ETP · 2.5% · $1M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
XENEXENON PHARMACEUTICALS INCNEW+42.5K42.5K+$2M$2M
RAPT THERAPEUTICS INCNEW+71.8K71.8K+$1M$1M
ALPINE IMMUNE SCIENCES INCNEW+181.9K181.9K+$1M$1M
HTHTH WORLD GROUP LTDNEW+31.0K31.0K+$1M$1M
PCVXVAXCYTE INCNEW+26.8K26.8K+$1M$1M
PLRXPLIANT THERAPEUTICS INCNEW+66.1K66.1K+$1M$1M
SEAGEN INCNEW+8.0K8.0K+$1M$1M
POINT BIOPHARMA GLOBAL INCNEW+127.1K127.1K+$926,486$926,486

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2022

58 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ACTIVISION BLIZZARD INCCOM13.80%$8M103.1K
2EXECHESAPEAKE ENERGY CORP.history →COM6.51%$4M39.5K
3ABXBARRICK GOLD CORP.history →COM6.00%$3M200.0K
4RDNTRADNET INChistory →COM3.67%$2M111.4K
5FTCHQFARFETCH LTDhistory →ORD SH CL A3.44%$2M416.5K
6XENEXENON PHARMACEUTICALS INChistory →COM2.93%$2M42.5K
7SUSUNCOR ENERGY INC NEWhistory →COM2.57%$1M46.3K
8OXYOCCIDENTAL PETE CORPhistory →COM2.56%$1M23.3K
9RAPT THERAPEUTICS INCCOM2.49%$1M71.8K
10MSOSADVISORSHARES TRhistory →PURE US CANNABIS2.47%$1M202.0K
11ALPINE IMMUNE SCIENCES INCCOM2.34%$1M181.9K
12HTHTH WORLD GROUP LTDhistory →SPONSORED ADS2.30%$1M31.0K
13PCVXVAXCYTE INChistory →COM2.25%$1M26.8K
14PLRXPLIANT THERAPEUTICS INChistory →COM2.23%$1M66.1K
15NENOBLE CORP PLChistory →ORD SHS A2.12%$1M32.1K
16BILLBILL COM HLDGS INChistory →COM2.08%$1M10.9K
17TECKTECK RESOURCES LTDhistory →CL B1.86%$1M28.1K
18SEAGEN INCCOM1.80%$1M8.0K
19CVECENOVUS ENERGY INChistory →COM1.80%$1M53.0K
20POINT BIOPHARMA GLOBAL INCCOM1.62%$926,486127.1K
21IVERIC BIO INCCOM1.54%$883,16341.3K
22BABAALIBABA GROUP HLDG LTDhistory →SPONSORED ADS1.51%$863,2829.8K
23AEMAGNICO EAGLE MINES LTDhistory →COM1.49%$852,63616.4K
24CINCOR PHARMA INCCOM1.45%$830,27667.6K
25CRCCALIFORNIA RES CORPhistory →COM STOCK1.43%$817,33518.8K
26ACRSACLARIS THERAPEUTICS INChistory →COM1.40%$802,68351.0K
27HRTXHERON THERAPEUTICS INChistory →COM1.39%$795,020318.0K
28RAREULTRAGENYX PHARMACEUTICAL INhistory →COM1.39%$792,93817.1K
29OPTINOSE INCCOM1.28%$730,264394.7K
30UBERUBER TECHNOLOGIES INChistory →COM1.26%$722,11629.2K
31VENTYX BIOSCIENCES INCCOM1.15%$656,94820.0K
32VKTXVIKING THERAPEUTICS INChistory →COM1.06%$608,67864.8K
33DAY ONE BIOPHARMACEUTICALS ICOM1.02%$585,83927.2K
34CCJCAMECO CORPhistory →COM1.02%$582,61925.7K
35PTCTPTC THERAPEUTICS INChistory →COM1.01%$576,59615.1K
36AEROVATE THERAPEUTICS INCCOM0.97%$554,56118.9K
37PAASPAN AMERN SILVER CORPCOM0.88%$503,27230.8K
38TVTXTRAVERE THERAPEUTICS INCCOM0.87%$499,46323.8K
39CYMABAY THERAPEUTICS INCCOM0.85%$485,91977.5K
40SRPTSAREPTA THERAPEUTICS INCCOM0.83%$472,9673.6K
41EQTEQT CORPCOM0.72%$412,72612.2K
42KALVISTA PHARMACEUTICALS INCCOM0.62%$356,86052.8K
43AMLXAMYLYX PHARMACEUTICALS INCCOM0.61%$350,9889.5K
44MLTXMOONLAKE IMMUNOTHERAPEUTICSCLASS A ORD0.59%$337,35532.1K
45INTERCEPT PHARMACEUTICALS INCOM0.57%$327,10026.4K
46ABOSACUMEN PHARMACEUTICALS INCCOM0.53%$301,47755.8K
47MIRATI THERAPEUTICS INCCOM0.53%$301,3126.7K
48VERVE THERAPEUTICS INCCOM0.51%$290,25015.0K
49BDQMALBIREO PHARMA INCCOM0.50%$288,79613.4K
50LRMRLARIMAR THERAPEUTICS INCCOM0.46%$262,99863.7K
51BERRY CORPCOM0.43%$248,00031.0K
52ALLBIRDS INCCOM CL A0.42%$242,000100.0K
53PRECISION BIOSCIENCES INCCOM0.40%$226,177190.1K
54GRACELL BIOTECHNOLOGIES INCSPONSORED ADS0.39%$225,67698.1K
55RRCRANGE RES CORPCOM0.39%$225,1809.0K
56SOUTHWESTERN ENERGY COCOM0.38%$216,45037.0K
57GENERATION BIO COCOM0.35%$200,92551.1K
58MAGENTA THERAPEUTICS INCCOM0.03%$18,63247.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2023$28M15Feb 12, 202413F-HRchanges · EDGAR ↗
Q3 2023$35M24Oct 27, 202313F-HRchanges · EDGAR ↗
Q2 2023$27M19Jul 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$32M22May 3, 202313F-HRchanges · EDGAR ↗
Q4 2022$57M59Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$47M35Nov 10, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$118M108Aug 5, 202213F-HRchanges · EDGAR ↗
Q1 2022$159M142May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$154M125Jan 26, 202213F-HRchanges · EDGAR ↗
Q3 2021$168M112Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$220M114Aug 12, 202113F-HRchanges · EDGAR ↗
Q1 2021$158M100May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$198M88Feb 10, 202113F-HRchanges · EDGAR ↗
Q3 2020$203M57Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$148M46Aug 12, 202013F-HRchanges · EDGAR ↗
Q1 2020$97M40May 7, 202013F-HRchanges · EDGAR ↗
Q4 2019$165M43Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$158M40Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$138M42Aug 8, 201913F-HRchanges · EDGAR ↗
Q1 2019$107M35May 10, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M35Feb 5, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.